openPR Logo
Press release

Ulcerative Colitis Market

06-21-2017 04:38 PM CET | Health & Medicine

Press release from: Pharmaceutical By CMI

Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained weight loss, loss of appetite, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones and liver disease. The diagnosis of this disease can be carried out by physical examination using tests such as colonoscopy, endoscopy, biopsy, CT scan and blood test.
If ulcerative colitis persists for over 8 years or longer, it may lead to colon cancer. The people having mild symptoms of this disease can be cured by over the counter drugs such as Imodium therapy. However, transcription medicine such as steroid medicines and amino salicylates are widely used to treat the condition. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps prevent colon cancer.

Also, some genetically engineered drugs also used to treat ulcerative colitis. These drugs are made up of certain living organisms that help suppress the inflammation, by targeting the inflammatory proteins such as cytokines. Some genetically engineered drugs approved by the U.S. FDA for treatment of the condition are Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade) and Vedolizumab (Entyvio).
These genetically engineered drugs may show some side effects such as fever, headache, hives, low blood pressure, breathing difficulties, back pain, and stomach pain. Also, these drugs may affect the immunity power of body to fight infection.
The exact cause for ulcerative colitis is unknown, though possible reasons are may be genetic factors, environmental changes, or weakened immune system. The ulcerative colitis can be prevented by simple healthy habits such as eating small meals throughout the day, staying well hydrated throughout the day, avoiding fatty foods, and limiting intake of high-fiber food.

According to data released by the Centers for Disease Control and Prevention (CDC), there are around 2.2 to 14.3 cases found per 100,000 population per year. Also, according to a study conducted in 2014 by Crohn’s & Colitis Foundation of America (CCFA), 907,000 people suffered from ulcerative colitis in the U.S. (data based on the research conducted in between 2011-2014 by CCFA)

Request a sample copy of this report@
https://www.coherentmarketinsights.com/insight/request-sample/238

Ulcerative colitis market taxonomy:
Global Market by Drug Type
Infliximab
Golimumab
Adalimumab
Vedolizumab
Mesalamine
Budesonide
Balsazide
Global Market by Dosage Form
Parenteral
Oral
Global Market by Geography
North America
Europe
APAC
Latin America
Middle East
Africa

High prevalence in developed regions and increasing incidence rate in emerging economies will play major role in driving growth of the ulcerative colitis market
According to the study of CCFA, industrialized countries have highest incidence rate for ulcerative colitis. This disease is most prevalent in urban areas than in rural areas, also it can affect to any age group of people but most cases diagnosed are of the age in between 15 to 35. According the stats of World Gastroenterology Organization (WGO), there is rising incidence rate in emerging economies such as India. Due to changing diet and lifestyle pattern, the emerging economies will show high growth rate in incidence rate of ulcerative colitis in the near future.
According to data collected from various sources and compiled by Coherent Market Insights, Europe have the highest annual rate of incidence worldwide, followed by North America and the lowest in Asia and Middle East.
However, North America holds the largest share in the global ulcerative colitis market due to continuous improvements in drugs, increased uptake of medicines, awareness about treatment and increasing clinical research. APAC region will show high growth in ulcerative colitis market during forecast years (2017-2024), due to raising awareness about the treatment, changing lifestyle will cause to increase prevalence and incidence rate, entry of new drugs in the market also some companies losing their patent of ulcerative drugs in coming years, like Humira (adalimumab) lost its patent in 2016 and Remicade will lose its patent in 2018. Also, some drugs companies have launched their biosimilar drugs in ulcerative colitis industry. For example, in 2016, India-based Torrent Pharmaceuticals launched a biosimilar drug under the brand name Adfra to compete Humira. Humira is a trade name for adalimumab medication owned by AbbVie Inc.
Some major companies playing leading role in ulcerative colitis market are AbbVie Inc., Hospira, Celltrion Healthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner Chilcott, Janssen Pharmaceuticals Inc. and Takeda Pharmaceuticals Company Ltd.
Some leading drugs are used to reduce inflammation and swelling and to cure ulcerative colitis are include Sulfasalazine (Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide (Colazal), and Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira), Infliximab (Remicade).

Get More Details about this Report@
https://www.coherentmarketinsights.com/ongoing-insight/ulcerative-colitis-market-238

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ulcerative Colitis Market here

News-ID: 589228 • Views: 245

More Releases from Pharmaceutical By CMI

Southern Blotting Market: Global Industry Insights Analysis and Opportunity Asse …
North America to dominate the southern blotting market owing to increased government funding and availability of technologies in the region The southern blotting market report covers market analysis across regions – North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Global southern blotting market is witnessing a positive trend with North America and Europe as the main engine of growth. North America and Europe are expected to capture a major
Pet Health Products Market
A pet or companion animal is an animal kept primarily for one's company, protection, or entertainment. Popular pets are regularly noted for their attractive appearances and their loyal or playful personalities. While dogs and cats are the most preferred pet animals, people also keep house rabbits, fancy rats, guinea pigs, parrots, chickens, and aquatic pets. The trend of pet adoption and keeping is gaining rapid traction across the globe. The
Prefilled Syringes Market
Parenteral drugs are the second most preferred type of drugs after oral solid dosage forms and also holds second largest market share in terms of revenue in overall pharmaceutical market. Various benefits such as ease in administration, better patient compliance and 100% bioavailability are the few important factors that are expected to favor growth of the prefilled syringes market over the forecast period (2016–2024). Prefilled syringes segment is the one
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the

All 5 Releases


More Releases for Humira

Global Humira Market Report 2019 Companies included AbbVie, Abbott, Knoll, Pfize …
Market Reports Company has recently published 7th edition of Humira Market Report which covers historic data of year 2013 to 2018 along with a forecast till year 2026. For inquiry or free sample pages email us at: sales@marketreportscompany.com The report provides a comprehensive view on the current state and future prospects of the market which analyzes different strategies for business growth. The global Humira market was valued at USD xx Million in
Humira Market by Top Key Players - AbbVie, Eisai, Cadila Healthcare, Torrent Pha …
Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation. Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa. A new report titled “Global Humira Market” has been added to the vast company database, thus adding value to the
Humira Market – Business Growth Opportunities during 2018 - 2025
This report studies the global Humira market status and forecast, categorizes the global Humira market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Ask for Sample copy of this report at https://www.inforgrowth.com/samplerequest/global-humira-market-research-report-2018. The following manufacturers are covered in this report: AbbVie, Abbott, Knoll, Pfizer, Johnson & Johnson, CAT. Humira Breakdown
Humira Market Major Manufacturers, Production and Market Comparison Analysis by …
Global Humira Market Research Report provides insights of Humira industry over past 5 years and a forecast until 2025.Report studies the Humira Market status and future trend in global market, splits Humira by type and by applications, to fully and deeply research and reveal the market situation and future forecast. Humira Market report would come in handy to understand your competitors and give you an insight about sales; volumes, revenues
Humira (Adalimumab) Market: Classification, Opportunities, Types and Application …
Humira (Adalimumab) basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis. Global Humira (Adalimumab)) Market, provides a basic overview of
Global Humira Market 2018 - AbbVie, Abbott, Knoll, Pfizer, Johnson & Johnson, CA …
Apex Market Reports, recently published a detailed market research study focused on the “Humira Market” across the global, regional and country level. The report provides 360° analysis of “Humira Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Humira on the basis of